vs
ARTIVION, INC.（AORT）与Repay Holdings Corp（RPAY）财务数据对比。点击上方公司名可切换其他公司
ARTIVION, INC.的季度营收约是Repay Holdings Corp的1.5倍（$116.0M vs $78.6M），ARTIVION, INC.净利率更高（2.1% vs -178.3%，领先180.4%），ARTIVION, INC.同比增速更快（19.2% vs 0.4%），Repay Holdings Corp自由现金流更多（$23.2M vs $-7.9M），过去两年ARTIVION, INC.的营收复合增速更高（9.1% vs -1.3%）
Artivion, Inc.是一家专注于心血管移植领域的医疗企业，主要供应经深低温冷冻保存的人体组织，同时研发各类医疗器械。旗下核心产品包括经过特殊处理、去除多余细胞物质与抗原的人体心脏瓣膜，以及BioGlue手术粘合剂，可为临床诊疗提供专业支持。
Repay Holdings Corp是一家聚焦北美市场的支付技术服务商，为零售、医疗、汽车服务、电商等领域的企业提供整合支付处理方案，涵盖银行卡收单、ACH转账、POS系统集成等数字化支付工具，助力客户简化交易流程、提升运营效率。
AORT vs RPAY — 直观对比
营收规模更大
AORT
是对方的1.5倍
$78.6M
营收增速更快
AORT
高出18.8%
0.4%
净利率更高
AORT
高出180.4%
-178.3%
自由现金流更多
RPAY
多$31.2M
$-7.9M
两年增速更快
AORT
近两年复合增速
-1.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $116.0M | $78.6M |
| 净利润 | $2.4M | $-140.1M |
| 毛利率 | 63.1% | 74.2% |
| 营业利润率 | 9.2% | -182.2% |
| 净利率 | 2.1% | -178.3% |
| 营收同比 | 19.2% | 0.4% |
| 净利润同比 | 114.7% | -3304.1% |
| 每股收益（稀释后） | $0.06 | $-1.68 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AORTRPAY
| Q4 25 | $116.0M | $78.6M | ||
| Q3 25 | $113.4M | $77.7M | ||
| Q2 25 | $113.0M | $75.6M | ||
| Q1 25 | $99.0M | $77.3M | ||
| Q4 24 | $97.3M | $78.3M | ||
| Q3 24 | $95.8M | $79.1M | ||
| Q2 24 | $98.0M | $74.9M | ||
| Q1 24 | $97.4M | $80.7M |
净利润AORTRPAY
| Q4 25 | $2.4M | $-140.1M | ||
| Q3 25 | $6.5M | $-6.4M | ||
| Q2 25 | $1.3M | $-102.3M | ||
| Q1 25 | $-505.0K | $-7.9M | ||
| Q4 24 | $-16.5M | $-4.1M | ||
| Q3 24 | $-2.3M | $3.2M | ||
| Q2 24 | $-2.1M | $-4.1M | ||
| Q1 24 | $7.5M | $-5.2M |
毛利率AORTRPAY
| Q4 25 | 63.1% | 74.2% | ||
| Q3 25 | 65.6% | 74.4% | ||
| Q2 25 | 64.7% | 75.7% | ||
| Q1 25 | 64.2% | 75.9% | ||
| Q4 24 | 63.2% | 76.3% | ||
| Q3 24 | 63.7% | 77.8% | ||
| Q2 24 | 64.6% | 78.2% | ||
| Q1 24 | 64.6% | 76.2% |
营业利润率AORTRPAY
| Q4 25 | 9.2% | -182.2% | ||
| Q3 25 | 11.1% | -3.9% | ||
| Q2 25 | 7.4% | -138.7% | ||
| Q1 25 | 2.2% | -4.7% | ||
| Q4 24 | 2.7% | -1.5% | ||
| Q3 24 | 4.6% | -0.9% | ||
| Q2 24 | 6.6% | -4.6% | ||
| Q1 24 | 26.0% | -3.1% |
净利率AORTRPAY
| Q4 25 | 2.1% | -178.3% | ||
| Q3 25 | 5.7% | -8.3% | ||
| Q2 25 | 1.2% | -135.2% | ||
| Q1 25 | -0.5% | -10.3% | ||
| Q4 24 | -16.9% | -5.3% | ||
| Q3 24 | -2.4% | 4.1% | ||
| Q2 24 | -2.2% | -5.4% | ||
| Q1 24 | 7.7% | -6.5% |
每股收益（稀释后）AORTRPAY
| Q4 25 | $0.06 | $-1.68 | ||
| Q3 25 | $0.13 | $-0.08 | ||
| Q2 25 | $0.03 | $-1.15 | ||
| Q1 25 | $-0.01 | $-0.09 | ||
| Q4 24 | $-0.40 | $-0.04 | ||
| Q3 24 | $-0.05 | $0.03 | ||
| Q2 24 | $-0.05 | $-0.04 | ||
| Q1 24 | $0.18 | $-0.06 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $64.9M | $115.7M |
| 总债务越低越好 | $215.1M | $280.1M |
| 股东权益账面价值 | $448.2M | $484.4M |
| 总资产 | $884.8M | $1.2B |
| 负债/权益比越低杠杆越低 | 0.48× | 0.58× |
8季度趋势，按日历期对齐
现金及短期投资AORTRPAY
| Q4 25 | $64.9M | $115.7M | ||
| Q3 25 | $73.4M | $95.7M | ||
| Q2 25 | $53.5M | $162.6M | ||
| Q1 25 | $37.7M | $165.5M | ||
| Q4 24 | $53.5M | $189.5M | ||
| Q3 24 | $56.2M | $168.7M | ||
| Q2 24 | $55.0M | $147.1M | ||
| Q1 24 | $51.1M | $128.3M |
总债务AORTRPAY
| Q4 25 | $215.1M | $280.1M | ||
| Q3 25 | $214.9M | $279.5M | ||
| Q2 25 | $215.6M | $279.0M | ||
| Q1 25 | $314.7M | $497.6M | ||
| Q4 24 | $314.3M | $496.8M | ||
| Q3 24 | $314.0M | $496.2M | ||
| Q2 24 | $313.6M | $435.6M | ||
| Q1 24 | $313.3M | $434.9M |
股东权益AORTRPAY
| Q4 25 | $448.2M | $484.4M | ||
| Q3 25 | $438.7M | $616.9M | ||
| Q2 25 | $419.9M | $633.7M | ||
| Q1 25 | $294.3M | $755.7M | ||
| Q4 24 | $276.2M | $761.3M | ||
| Q3 24 | $304.7M | $754.7M | ||
| Q2 24 | $295.1M | $815.4M | ||
| Q1 24 | $295.0M | $813.8M |
总资产AORTRPAY
| Q4 25 | $884.8M | $1.2B | ||
| Q3 25 | $857.7M | $1.3B | ||
| Q2 25 | $838.4M | $1.4B | ||
| Q1 25 | $791.2M | $1.5B | ||
| Q4 24 | $789.1M | $1.6B | ||
| Q3 24 | $803.1M | $1.6B | ||
| Q2 24 | $789.5M | $1.5B | ||
| Q1 24 | $784.0M | $1.5B |
负债/权益比AORTRPAY
| Q4 25 | 0.48× | 0.58× | ||
| Q3 25 | 0.49× | 0.45× | ||
| Q2 25 | 0.51× | 0.44× | ||
| Q1 25 | 1.07× | 0.66× | ||
| Q4 24 | 1.14× | 0.65× | ||
| Q3 24 | 1.03× | 0.66× | ||
| Q2 24 | 1.06× | 0.53× | ||
| Q1 24 | 1.06× | 0.53× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $19.6M | $23.3M |
| 自由现金流经营现金流 - 资本支出 | $-7.9M | $23.2M |
| 自由现金流率自由现金流/营收 | -6.9% | 29.6% |
| 资本支出强度资本支出/营收 | 23.7% | 0.1% |
| 现金转化率经营现金流/净利润 | 8.06× | — |
| 过去12个月自由现金流最近4个季度 | $839.0K | $90.7M |
8季度趋势，按日历期对齐
经营现金流AORTRPAY
| Q4 25 | $19.6M | $23.3M | ||
| Q3 25 | $22.3M | $32.2M | ||
| Q2 25 | $15.0M | $33.1M | ||
| Q1 25 | $-17.0M | $2.5M | ||
| Q4 24 | $10.1M | $34.3M | ||
| Q3 24 | $11.5M | $60.1M | ||
| Q2 24 | $6.1M | $31.0M | ||
| Q1 24 | $-5.5M | $24.8M |
自由现金流AORTRPAY
| Q4 25 | $-7.9M | $23.2M | ||
| Q3 25 | $17.7M | $32.1M | ||
| Q2 25 | $11.7M | $33.0M | ||
| Q1 25 | $-20.6M | $2.4M | ||
| Q4 24 | $8.7M | $34.0M | ||
| Q3 24 | $7.8M | $59.8M | ||
| Q2 24 | $3.6M | $30.5M | ||
| Q1 24 | $-9.1M | $24.7M |
自由现金流率AORTRPAY
| Q4 25 | -6.9% | 29.6% | ||
| Q3 25 | 15.6% | 41.3% | ||
| Q2 25 | 10.4% | 43.6% | ||
| Q1 25 | -20.8% | 3.0% | ||
| Q4 24 | 9.0% | 43.5% | ||
| Q3 24 | 8.2% | 75.6% | ||
| Q2 24 | 3.7% | 40.7% | ||
| Q1 24 | -9.3% | 30.6% |
资本支出强度AORTRPAY
| Q4 25 | 23.7% | 0.1% | ||
| Q3 25 | 4.1% | 0.2% | ||
| Q2 25 | 2.9% | 0.1% | ||
| Q1 25 | 3.7% | 0.2% | ||
| Q4 24 | 1.5% | 0.3% | ||
| Q3 24 | 3.8% | 0.3% | ||
| Q2 24 | 2.6% | 0.6% | ||
| Q1 24 | 3.7% | 0.1% |
现金转化率AORTRPAY
| Q4 25 | 8.06× | — | ||
| Q3 25 | 3.42× | — | ||
| Q2 25 | 11.16× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 18.52× | ||
| Q2 24 | — | — | ||
| Q1 24 | -0.73× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AORT
| Aortic Stent Grafts | $43.3M | 37% |
| On X | $27.8M | 24% |
| Preservation Services | $24.1M | 21% |
| Surgical Sealants | $20.3M | 18% |
| Other Products | $463.0K | 0% |
RPAY
| Sales Channel Directly To Consumer | $69.4M | 88% |
| Other | $6.8M | 9% |
| Sales Channel Through Intermediary | $2.3M | 3% |
